GENFIT to Test Nangibotide in ACLF Phase 2 Trial After Summer Acquisition
Event summary
- GENFIT acquired nangibotide in summer 2026, a late-stage asset targeting ACLF via the TREM-1 pathway.
- Phase 2a proof-of-concept trial in ACLF expected to start Q4 2026, with data readout targeted for 2027.
- Nangibotide has shown efficacy signals in prior Phase 2 trials, including reduced mortality in severe COVID-19.
- Over 400 subjects exposed to nangibotide across four clinical trials with favorable safety profile.
- GENFIT will present more details at The Liver Meeting® in November 2026.
The big picture
GENFIT's acquisition of nangibotide reinforces its focus on rare, life-threatening liver diseases, particularly ACLF. The move comes after the company's 2024 FDA approval of Iqirvo® for Primary Biliary Cholangitis, signaling continued expansion in liver disease therapeutics. With Ipsen as a major shareholder, GENFIT is positioning itself as a leader in addressing high unmet medical needs in hepatology.
What we're watching
- Clinical Validation
- Whether nangibotide's efficacy signals in septic shock and COVID-19 translate to ACLF.
- Regulatory Pathway
- The pace at which GENFIT advances nangibotide through Phase 2, given its existing safety data.
- Pipeline Strategy
- How GENFIT integrates nangibotide into its broader ACLF portfolio alongside Iqirvo®.
Related topics